CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Petros Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Petros Pharmaceuticals Inc
1185 Avenue Of The Americas
3Rd Floor, Suite 570
Phone: (973) 242-0005p:973 242-0005 NEW YORK, NY  10036  United States Ticker: PTPIPTPI
Business Summary
Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs. The Company is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. It also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
3841 Surgical and medical instruments and apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board John D.Shulman 59 1/1/2020 1/1/2020
President, Chief Commercial Officer FadyBoctor 46 1/1/2020 1/1/2020
Independent Vice Chairman of the Board Joshua N.Silverman 53 1/1/2020 1/1/2020
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Metuchen Pharmaceuticals LLC
Neurotrope, Inc.
Pos-T-Vac, LLC
PTPI
Timm Medical Technologies, Inc.

General Information
Number of Employees: 21 (As of 12/31/2023)
Outstanding Shares: 6,875,814 (As of 3/26/2024)
Shareholders: 297
Stock Exchange: NASD
Federal Tax Id: 851410058
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024